Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis
Molecules · 2024
DOI: 10.3390/molecules29081802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Victoria Fonseca-Benítez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Investigación en Química Aplicada INQA, Química Farmacéutica, Universidad El Bosque, Bogotá 11001, Colombia. Hauptthemen laut MEDLINE: Breast Neoplasms, Aldo-Keto Reductase Family 1 Member C3, Drug Design, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diseño Racional de Farmacos UEB, Vicerrectoria de Investigaciones Universidad El Bosque, Bogotá, Colombia, Ministerio de Ciencia Tecnología e Innovación de Colombia for the National Doctorate scholarship.
Abstract (Originalsprache)
Breast cancer is a major global health issue, causing high incidence and mortality rates as well as psychological stress for patients. Chemotherapy resistance is a common challenge, and the Aldo-keto reductase family one-member C3 enzyme is associated with resistance to anthracyclines like doxorubicin. Recent studies have identified celecoxib as a potential treatment for breast cancer. Virtual screening was conducted using a quantitative structure–activity relationship model to develop similar drugs; this involved backpropagation of artificial neural networks and structure-based virtual screening. The screening revealed that the C-6 molecule had a higher affinity for the enzyme (−11.4 kcal/mol), a lower half-maximal inhibitory concentration value (1.7 µM), and a safer toxicological profile than celecoxib. The compound C-6 was synthesized with an 82% yield, and its biological activity was evaluated. The results showed that C-6 had a more substantial cytotoxic effect on MCF-7 cells (62%) compared to DOX (63%) and celecoxib (79.5%). Additionally, C-6 had a less harmful impact on healthy L929 cells than DOX and celecoxib. These findings suggest that C-6 has promising potential as a breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Investigación en Química Aplicada INQA, Química Farmacéutica, Universidad El Bosque, Bogotá 11001, Colombia.
ORCID-Profile: Victoria Fonseca-Benítez, Paola Acosta-Guzmán, Juan Esteban Sánchez, Ronald Andrés Jiménez, James Guevara-Pulido
Förderung
- Diseño Racional de Farmacos UEB
- Vicerrectoria de Investigaciones Universidad El Bosque, Bogotá, Colombia
- Ministerio de Ciencia Tecnología e Innovación de Colombia for the National Doctorate scholarship
Zitieren
APA
Fonseca-Benítez, V., Acosta-Guzmán, P., Sánchez, J. E., Alarcón, Z., Jiménez, R. A., & Guevara-Pulido, J. (2024). Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis. Molecules. https://doi.org/10.3390/molecules29081802
Vancouver
Fonseca-Benítez V, Acosta-Guzmán P, Sánchez JE, Alarcón Z, Jiménez RA, Guevara-Pulido J. Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis. Molecules. 2024. doi:10.3390/molecules29081802
BibTeX
@article{FonsecaBentez2024,
author = {Fonseca-Benítez, Victoria and Acosta-Guzmán, Paola and Sánchez, Juan Esteban and Alarcón, Zaira and Jiménez, Ronald Andrés and Guevara-Pulido, James},
title = {Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29081802}
}
EUVIMED